Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Andres Felipe Cardona Zorrilla"'
Autor:
Mauricio Lujan, Mauricio Lema, Beatriz Preciado, Camila Lema, Jorge Egurrola, Andres Felipe Cardona Zorrilla, Diego Mauricio Gonzalez, William Armando Mantilla, Luis Pino, Gustavo Rojas, Diego Andres Gomez-Abreo, Isabel Munevar, Raimundo Manneh, Ray Manneh Kopp, Jose F. Lobaton, Esteban Calle, Mariana Borras, Ivan Camilo Triana, Mateo Pineda, Diego Moran Ortio
Publikováno v:
Journal of Clinical Oncology. 40:e21094-e21094
e21094 Background: Nivolumab is a human programmed death receptor-1 (PD-1) blocking antibody, used as treatment option in patients with advanced non-small cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response
Autor:
Oscar Gerardo Arrieta, Luis Antonio Lara Mejía, Luis Antonio Cabrera, Maritza Ramos, David Jose Heredia, Graciela Cruz-Rico, Miguel Angel Salinas, Daniela Cardenas Fernández, Zyanya Lucía Zatarain-Barron, Andres Felipe Cardona Zorrilla, Jordi Remon Masip, Rafael Rosell
Publikováno v:
Journal of Clinical Oncology. 40:9074-9074
9074 Background: Alectinib is one of the standard treatment options as an upfront therapy in advanced ALK-rearranged non-small-cell lung cancer. However, all patients will eventually progress to target therapy, developing resistance mechanisms. Precl
Publikováno v:
European journal of cancer (Oxford, England : 1990). 149
Autor:
Norma Hernández-Pedro, Masao Yamamoto-Ramos, Oscar Gerardo Arrieta Rodriguez, Pedro Barrios-Bernal, Mario Orozco-Morales, Francisco Lozano, Zyanya Lucia Zatarain-Barrón, Maritza Ramos, Diana Flores-Estrada, Diego López, Federico Maldonado, Christian Rolfo, Bernardo Cacho, Andres Felipe Cardona Zorrilla, Graciela Cruz-Rico
Publikováno v:
Journal of Clinical Oncology. 39:9114-9114
9114 Background: Hypoxia has been associated with chemo-radioresistance secondary to Vascular Endothelial Growth Factor Receptor induced by Hypoxia Induced Factor (HIF). Nitroglycerin (NTG) can reduce HIF-1 in cell lines, and this may have anti-angio
Autor:
Jie Yang, Carlos González Pedraz, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Andres Felipe Cardona Zorrilla, Imane Chaib, Andrés Aguilar, Rongwei Sun, Martyna Filipska, Peng Cao, Jordi Codony-Servat, Eloisa Jantus-Lewintre, Itziar de Aguirre, Xueting Cai, Niki Karachaliou, David Llige, Mariacarmela Santarpia, Jing Miao, Rafael Rosell
Publikováno v:
Annals of Translational Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Ann Transl Med
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Ann Transl Med
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Background: Recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis with limited progressionfree survival and overall survival, even when treated with different combinations of chemotherapy, targeted therapies an
Autor:
Taofeek K. Owonikoko, X. Chen, Bin Zhao, Christian Schulz, Joanne Wagman, Jhanelle E. Gray, Terufumi Kato, Andres Felipe Cardona Zorrilla
Publikováno v:
Journal of Clinical Oncology. 38:TPS9632-TPS9632
TPS9632 Background: First-line treatment with pembrolizumab + pemetrexed/platinum improved clinical outcomes in patients with advanced nonsquamous NSCLC in KEYNOTE-021 and KEYNOTE-189. Poly(ADP-ribose) polymerase inhibitors (PARPi), including olapari
Autor:
Pilar Archila, Jenny Mireya Ávila Coy, Rafael Rosell, Luis Eduardo Pino, Christian Rolfo, Alejandro Ruiz-Patiño, Carlos Vargas, Zyanya Lucia Zatarain-Barrón, Diana Carolina Mayorga Gonzalez, Andres Felipe Cardona Zorrilla, July Rodriguez, Hernán Carranza, Feliciano Barrón, Jorge Otero, Luis Leonardo Rojas Puentes, Melissa Andrea Bravo Espinosa, Claudio Martin, Gonzalo Recondo, Diana Carolina Sotelo Rodríguez, Oscar Arrieta
Publikováno v:
Journal of Clinical Oncology. 38:e21569-e21569
e21569 Background: Human papilloma virus (HPV) is associated with the development of several primary tumors. Recent studies have shown that HPV-positive tumors tend to be sensitive to immune checkpoint inhibitors (ICI), owing to the presence of xenob
Autor:
Carlos Vargas, Zyanya Lucia Zatarain-Barrón, Jenny Mireya Ávila Coy, Luis Leonardo Rojas Puentes, Luis Eduardo Pino, Melissa Andrea Bravo Espinosa, Hernán Carranza, Oscar Arrieta, D. Mayorga, Jorge Otero, Andres Felipe Cardona Zorrilla, Claudio Martin, Rafael Rosell, July Rodriguez, Christian Rolfo, Alejandro Ruiz-Patiño, Gonzalo Recondo, Feliciano Barrón, Diana Carolina Sotelo Rodríguez, Pilar Archila
Publikováno v:
Journal of Clinical Oncology. 38:e21566-e21566
e21566 Background: Several histopathological markers have been associated with immune system activity and its relationship with clinical outcomes in lung cancer. Determination of tumor infiltrating lymphocytes as well as specific subpopulations could
Autor:
Yohann Loriot, Laurence Eliot Miles Krieger, Guy Faust, Michiel S. van der Heijden, Simon Fear, María José Méndez Vidal, Andrea Necchi, Zsuzsanna Papai, Olatz Etxaniz, Sabine de Ducla, Axel S. Merseburger, Consuelo Buttigliero, Nuria Lainez, Rosa Tambaro, Andres Felipe Cardona Zorrilla, Franco Morelli, Margitta Retz, Cora N. Sternberg, Maartje Los, Stefano Panni
Publikováno v:
Journal of Clinical Oncology. 38:488-488
488 Background: UTUC is rarer than bladder UC and typically responds poorly to standard chemotherapy. Analysis of 220 biomarker-evaluable atezo-treated patients (pts) in phase II/III trials suggested worse outcomes in UT vs lower tract UC [Galsky, ES
Autor:
Feliciano Barrón, Oscar Gerardo Arrieta Rodriguez, L. Cabrera, Andres Felipe Cardona Zorrilla
Publikováno v:
Journal of Clinical Oncology. 37:e18376-e18376
e18376 Background: Lung cancer is the leading cause of cancer-related mortality in México and worldwide. More than 80 percent of lung cancers are classified as non-small cell lung cancer (NSCLC). Immunotherapy has become integrated into the treatmen